Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Herman, A.
Right arrow Articles by Caspi, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herman, A.
Right arrow Articles by Caspi, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 8, No. 1, pp. 30-34, 1993
© 1993 European Society of Human Reproduction and Embryology

other

Overstimulated cycles under low-dose gonadotrophins in patients with polycystic ovary syndrome: characterization and management

Arie Herman1, Raphael Ron-El, Abraham Golan, Yigal Soffer, Ian Bukovsky and Eliahu Caspi

Department of Obstetrics and Gynaecology, Assaf Harofeh Medical Centre, Zerifin, Affiliated to Sackler School of Medicine, Tel Aviv University Israel

Correspondence: 1To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, Assaf Harofeh Medical Centre, Zerifin 70300, Israel

Among 30 patients with polycystic ovary syndrome, treated with low-dose gonadotrophins, 75 cycles were analysed in order to characterize overstimulated cycles that were at increased risk of developing ovarian hyperstimulation. Optimal response (one or two follicles ≥ 14 mm diameter) was observed in 59 cycles (79%). The remaining 16 cycles (21%) exhibited an overstimulated response characterized either by growing more than two follicles or having an oestradiol level > 850 pg/ml (2 SD above the mean observed in optimal cycles). Six of the latter were handled prospectively when oestradiol levels were found to be too high according to the size of the leading follicle. This stage was termed as developing overstimulation and its identification was based on objective criteria obtained from the optimal group. Following the withholding of gonadotrophin, the follicles continued to grow; however, the final oestradiol level was lower compared with six other matched overstimulated cycles. Overall, 14 patients conceived (47%) of whom three (21%) had multiple pregnancies. Mild or moderate ovarian hyperstimulation syndrome occurred in three cases; all of which involved overstimulated cycles. Low-dose gonadotrophin treatment is associated with a substantial degree of overstimulated response. All cycles should be monitored carefully in order to recognize the overstimulated response, which deserves cautious management.

Key words: low-dose HMG/ovarian overstimulation/PCOS


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
J. Balasch, F. Fabregues, M. Creus, B. Puerto, J. Penarrubia, and J. A. Vanrell
Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens
Hum. Reprod., April 1, 2001; 16(4): 652 - 656.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. J. P. van Santbrink and B. C. J. M. Fauser
Urinary Follicle-Stimulating Hormone for Normogonadotropic Clomiphene-Resistant Anovulatory Infertility: Prospective, Randomized Comparison between Low Dose Step-Up and Step-Down Dose Regimens
J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3597 - 3602.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. C. J. M. Fauser and A. M. van Heusden
Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences
Endocr. Rev., February 1, 1997; 18(1): 71 - 106.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.